Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Confirms Purchase of True Materials

NEW YORK (GenomeWeb News) – Affymetrix has confirmed that the unnamed company that it said last week that it had acquired is True Materials, a microparticle technology firm based in the University of California, San Francisco, Mission Bay Campus.
 
An Affymetrix spokesperson told GenomeWeb Daily News via e-mail that True Materials founder Randy True has joined Affy as a vice president of research and development.
 
True Materials is developing a digitally encoded microparticle technology that will enable the array manufacturer to enter low to mid-multiplex markets and compete with bead-based platforms. Affy said that the technology is also applicable to the research, applied, and diagnostic markets.
 
Affy disclosed the acquisition during its second-quarter conference call last week. Steve Fodor, chairman and CEO of the firm, said the technology "is more scalable and cost effective than bead-based approaches." It uses digital microparticles to carry out assays in solution, he said, and is "capable of multiplexing tests ranging up to several thousand markers."
 

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.